This study will help find out how well the COVID-19 vaccine (BNT162b2) may help protect against COVID-19 in people aged 50-64 years of age who don’t have any serious medical issues that put them at higher risk of severe COVID-19. The study will compare the COVID-19 vaccine to a placebo.
The purpose of this research is to test a new investigational vaccine VAX-31. We are doing this study to learn about the safety of VAX-31 and whether VAX-31 causes the body to make antibodies (germ‑fighting proteins in the blood).
The purpose of this study is to learn about the effects of cadisegliatin (also called “TTP399”) compared to placebo to find out if or how much cadisegliatin may reduce the episodes of low blood sugar (hypoglycemia) in T1DM, or lower HbA1c, and to see how people with T1DM feel and do when taking cadisegliatin (how the study drug is tolerated).
This study will evaluate the safety and efficacy of tirzepatide for the treatment of participants with MASLD who are at increased risk of major adverse liver outcome (MALO) events (high-risk MASLD).
We are doing this study to learn more about a new drug called AZD7760 when it is given as an intravenous (IV; into the vein) infusion to healthy adults (Phase I) or adults with end‑stage kidney disease who are on hemodialysis with a central venous catheter (Phase IIa).
We are doing this study to learn more about the benefits and safety of treatment of an experimental drug called baxdrostat in combination with dapagliflozin for treating patients with CKD and high blood pressure. We also want to better understand CKD and the health problems that come with it.
We are doing this study to learn more about how effective, safe and tolerable an experimental drug called balcinrenone is when used in combination with dapagliflozin for treating patients with heart failure and impaired kidney function and also to better understand the studied disease and associated health problems.
This study is being done to learn more about maridebart cafraglutide (MariTide [formerly AMG 133]) in people with heart failure (HF) and obesity in addition to their routine medical care.
The vaccine made in chicken cells has been tested in many studies and approved in several countries. BN wants to change to making the vaccine in quail cells. This process is easier. It would allow BN to produce many more doses of vaccines in another outbreak.
We want to learn if MVA‑BN that is made in quail cells is as safe as when it is made in chicken cells. We also want to know if MVA‑BN made in quail cells causes a similar immune response.
